NTX-250, a Multimodal mRNA-based Immunotherapy, Eradicates Large Established Tumors in a Stringent Mouse Model of HPV16-Driven Cancer
November 7, 2022
Society for Immunotherapy of Cancer Annual Meeting (2022)
For inquiries, please visit our Contact Page.
